Photo by Nikita Kostrykin on Unsplash
What Happened
32,000 sleep sessions. That's the dataset Whoop used to train the machine learning algorithm at the center of an 11-month regulatory fight — one that ended on June 23, 2026, when the FDA formally dropped its enforcement action against the fitness wearable company. As reported by Google News, drawing on original reporting from STAT News and Bloomberg, the resolution closes a chapter that briefly threatened to reshape how an entire category of consumer devices is regulated.
The conflict started on July 14, 2025, when the FDA sent Whoop a formal warning letter. According to the agency's official filing on FDA.gov, the problem wasn't the feature itself — it was the framing. Whoop's Blood Pressure Insights tool estimated daily blood pressure values without a traditional cuff, and its marketing included the claim that higher blood pressure may indicate poor sleep quality. The FDA argued that language tied the feature to diagnosing or treating hypertension, which pushed it out of the "general wellness" category and into medical device territory, requiring premarket clearance the company had never sought.
Whoop refused to back down. Bloomberg framed the 11-month standoff as a deliberate corporate decision, noting that CEO Will Ahmed publicly called the FDA's position "misguided" on LinkedIn in July 2025, arguing the feature belonged within the general wellness exemption established by the 21st Century Cures Act. The company declined to remove the feature during the dispute.
The resolution came through a policy shift, not a court ruling. On January 6, 2026, the FDA issued updated general wellness guidance that explicitly permitted blood pressure monitoring for non-diagnostic wellness purposes — creating regulatory space that did not exist when the original warning was written. Whoop adjusted its feature's language and marketing to align with the new framework. STAT News, which broke the June 23, 2026 resolution, also noted that the updated guidance was designed in part to ease oversight of AI-enabled digital health products more broadly.
Why This Regulatory Shift Matters for Health Tech Investors
The Whoop case isn't primarily about one wearable company's compliance headache. It's a preview of how a high-growth sector negotiates its boundaries with federal regulators — and for anyone evaluating health technology as part of an investment portfolio, the financial context around that negotiation is striking.
As of March 2026, Whoop closed a $575 million Series G funding round at a $10.1 billion valuation, nearly triple the company's $3.6 billion valuation from its previous financing round. The company reported $1.1 billion in annualized bookings in 2025 — up 103% year-over-year — with more than 2.5 million members and 1,481 employees as of May 31, 2026. Subscription pricing ranges from $199 per year for WHOOP One to $359 per year for WHOOP Life.
Chart: Whoop's valuation nearly tripled between its previous financing round and its March 2026 Series G close — all while the FDA enforcement action was active.
That growth happened in the shadow of the FDA dispute, which is itself an important signal. Regulatory risk didn't stop capital from flowing to Whoop — but it created real legal exposure. On November 18, 2025, a class action lawsuit was filed against the company in the Northern District of California, using the FDA warning letter as the evidentiary basis for consumer fraud claims. The regulatory resolution removes that anchor from the plaintiff's argument, which may significantly affect the lawsuit's trajectory.
The January 2026 guidance update also reshapes the competitive landscape. The FDA's new framework opens the door for other wearable makers to add blood pressure monitoring features under a wellness exemption without seeking premarket approval — provided they stay within non-diagnostic framing. Apple Watch received FDA clearance for a hypertension detection feature in September 2025, representing a higher regulatory bar. Aktiia's Hilo wristband earned over-the-counter FDA clearance as a cuffless blood pressure monitor for medical use in 2026, a different category again. These three regulatory events together define three distinct product tiers — wellness estimation, detection-with-clearance, and standalone medical-grade measurement — each carrying different compliance obligations and investment risk profiles.
Photo by Mockup Graphics on Unsplash
The Machine Learning Engine Behind the Standoff
Understanding what the Blood Pressure Insights feature actually does clarifies why the regulatory line was genuinely difficult to draw — and why AI is central to this story, not incidental to it.
The feature uses photoplethysmography (PPG) sensors — the optical sensors on the back of the wearable that measure blood flow through skin — combined with heart rate variability and pulse wave timing data collected during sleep. A machine learning model trained on over 32,000 sleep sessions from more than 11,000 Whoop members interprets those signals to estimate blood pressure values. Critically, the feature requires three separate calibration readings from a traditional arm cuff before it activates, anchoring its outputs to conventional measurements rather than operating as a standalone diagnostic instrument.
That calibration requirement was likely central to Whoop's regulatory argument, and it illustrates a broader challenge for the FDA. Traditional medical device review was designed for hardware with fixed, testable parameters — not for machine learning models that are continuously updated on population-scale datasets. The agency's January 2026 guidance update reflects an institutional acknowledgment that AI-enabled wellness features require a different regulatory lens than traditional diagnostic devices. In June 2026, separately, University of Utah researchers announced a new smartwatch technology using electrical impedance for continuous blood pressure measurement — suggesting the technical frontier is advancing faster than any single guidance update can anticipate.
Three Questions Worth Watching
Does the class action survive? The November 2025 lawsuit was constructed around the FDA warning letter as evidence that Whoop's product claims were fraudulent. With the FDA having dropped enforcement and updated its guidance to accommodate the feature, the primary regulatory support for that theory is gone. How the plaintiffs reformulate their argument — if they proceed at all — will be worth tracking.
What does the FDA leadership vacancy mean for this sector? FDA Commissioner Marty Makary resigned on May 12, 2026, after just 13 months in office. The January 2026 guidance expanding wellness exemptions, and the subsequent decision to drop the Whoop enforcement action, unfolded partly under his watch. Whether the agency's next confirmed leader maintains a permissive posture toward AI-enabled consumer health features is not guaranteed, and that uncertainty matters for financial planning around any health tech position.
Where exactly is the wellness-versus-medical line? Academic analysis published in the Journal of Medical Internet Research noted that the updated guidance has been criticized as ambiguous about precisely where the boundary sits. Hypertension experts have raised concerns that cuffless wearable blood pressure features "are not yet proven to be accurate" and lack independent peer-reviewed validation. The exemption exists, but the evidentiary standard for wellness claims remains contested — meaning the next enforcement action in this space could redraw the line again.
Frequently Asked Questions
How does Whoop measure blood pressure without a cuff?
Whoop's Blood Pressure Insights uses optical sensors on the wearable to capture photoplethysmography (PPG) data — light-based readings of blood flow through the skin — alongside heart rate variability and pulse wave timing recorded during sleep. A machine learning algorithm trained on over 32,000 sleep sessions from more than 11,000 members interprets those signals to estimate blood pressure values. The feature requires three separate calibration readings from a conventional arm cuff before it activates, anchoring the estimates to real cuff measurements rather than operating independently.
Do wearables need FDA approval for blood pressure monitoring in 2026?
It depends on how the feature is framed. As of the FDA's updated general wellness guidance issued on January 6, 2026, blood pressure monitoring for non-diagnostic wellness purposes is explicitly permitted without premarket clearance under the 21st Century Cures Act. However, if marketing language ties blood pressure readings to diagnosing or treating hypertension, the product crosses into regulated medical device territory. Apple Watch received FDA clearance for a hypertension detection feature in September 2025 — a separate, higher regulatory category than the wellness framing Whoop now uses.
Is Whoop blood pressure monitoring accurate enough to rely on?
This remains an open clinical question. Whoop trained its algorithm on a large dataset and requires cuff calibration to anchor estimates to conventional readings. However, hypertension experts have publicly stated that cuffless wearable blood pressure devices "are not yet proven to be accurate" and that independent peer-reviewed validation is lacking across the category. The FDA's general wellness framing does not require accuracy validation to the standard of a medical device. Anyone managing hypertension should use a validated cuff device and discuss any wearable data with a healthcare provider — not treat it as clinical-grade measurement.
Bottom Line
The Whoop-FDA standoff ended not because either side fully prevailed, but because the regulatory ground beneath the dispute shifted. The January 2026 guidance update created space that simply didn't exist when the warning letter was issued in July 2025, and Whoop adjusted its language to fit through that opening.
For anyone tracking digital health as part of a broader personal finance or investment picture, the case offers a concrete framework: regulatory risk in health tech is real, can accelerate in both directions without warning, and doesn't necessarily stop capital formation — Whoop raised $575 million and hit a $10.1 billion valuation during the dispute itself.
In my read of the data, the variable most worth monitoring going forward isn't whether Whoop's algorithm is accurate enough (that debate will play out in academic literature over years) — it's whether the FDA's current permissive posture toward AI-enabled wellness features survives a leadership transition. The January 2026 guidance is a policy document, not a statute. The next confirmed commissioner can revise it, and there are credible voices in the clinical community who would welcome a tighter standard. That policy uncertainty is the real unpriced risk in the wearable health sector right now.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, medical, or investment advice. Consult a qualified professional before making financial or health decisions. Research based on publicly available sources current as of June 24, 2026.